{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125340","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.356405+00:00","generated_at":"2026-05-30T01:41:51.910721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eledon completes BESTOW enrollment early; reports $77M net income on non-cash gain","bullets":["Phase 2 BESTOW trial for tegoprubart in kidney transplant hit target of 120 patients ~4 months ahead of schedule.","First two islet transplant recipients with type 1 diabetes achieved insulin independence on tegoprubart without tacrolimus.","Completed oversubscribed $85M offering in October; net proceeds ~$79.5M extend cash runway to end of 2026.","Q3 2024 net income $77M ($1.05 basic EPS) includes $96.4M non-cash fair value gain; adjusted net loss $19.5M.","Cash and short-term investments $78.2M at Sep 30, 2024; R&D expenses rose to $16.5M from $7.9M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125340","json":"https://secwatch.observer/filing/0000950170-24-125340.json","markdown":"https://secwatch.observer/filing/0000950170-24-125340.md","text":"https://secwatch.observer/filing/0000950170-24-125340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/0000950170-24-125340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/eldn-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:41:51.910721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}